OpenLB
Open Library of Bioscience

20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval.

Abstract

References

1. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(suppl 5):45–51. [DOI: 10.1111/1469-0691.12461]
2. Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–57. [DOI: 10.1016/S2214-109X(18)30247-X]
3. Centers for Disease Control and Prevention. Pneumococcal disease. 2022. https://www.cdc.gov/pneumococcal/index.html . Accessed 30 Jun 2023.
4. Wiese AD, Griffin MR, Grijalva CG. Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18(4):327–41. [DOI: 10.1080/14760584.2019.1582337]
5. Vadlamudi NK, Chen A, Marra F. Impact of the 13-valent pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis. Clin Infect Dis. 2019;69(1):34–49. [DOI: 10.1093/cid/ciy872]
6. Perdrizet J, Horn EK, Hayford K, et al. Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England and Wales, Israel, and the United States. Infect Dis Ther. 2023. https://doi.org/10.1007/s40121-023-00798-x . [DOI: 10.1007/s40121-023-00798-x]
7. Huang L, Wasserman M, Grant L, et al. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022;40(33):4700–8. [DOI: 10.1016/j.vaccine.2022.06.024]
8. Janssens E, Flamaing J, Vandermeulen C, et al. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. Acta Clin Belg. 2023;78(1):78–86. [DOI: 10.1080/17843286.2022.2039865]
9. US FDA. PREVNAR 20 (pneumococcal 20-valent conjugate vaccine), suspension for intramuscular injection: US prescribing information. 2023. https://www.fda.gov/media/149987/download . Accessed 30 Jun 2023.
10. US FDA. PREVNAR 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM protein]), suspension for intramuscular injection: US prescribing information. 2017. https://www.fda.gov/media/107657/download . Accessed 30 Jun 2023.
11. US FDA. Pneumococcal 7-valent conjugate vaccine (diphtheria CRM protein) - Prevnar: US prescribing information. 2008. https://www.fda.gov/media/76076/download . Accessed 30 Jun 2023.
12. Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019;37(42):6201–7. [DOI: 10.1016/j.vaccine.2019.08.048]
13. Shirley M. 20-valent pneumococcal conjugate vaccine: a review of its use in adults. Drugs. 2022;82(9):989–99. [DOI: 10.1007/s40265-022-01733-z]
14. US FDA. Approval letter - PREVNAR20. 2021. https://www.fda.gov/media/150021/download . Accessed 30 Jun 2023.
15. European Medicines Agency. Apexxnar suspension for injection in pre-filled syringe - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed): summary of product characteristics. 2023. https://www.ema.europa.eu/en/documents/product-information/apexxnar-epar-product-information_en.pdf . Accessed 30 Jun 2023.
16. US FDA. Approval letter - PREVNAR20. 2023. https://www.fda.gov/media/167637/download . Accessed 30 Jun 2023.
17. Pfizer Inc. U.S. FDA accepts for priority review the supplemental Biologics License Application for Pfizer's 20-valent pneumococcal conjugate vaccine in infants and children [media release]. 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-priority-review-supplemental-biologics . Accessed 30 Jun 2023.
18. Pfizer Inc. Pfizer reports third-quarter 2017 results [media release]. 2017. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_reports_third_quarter_2017_results . Accessed 30 Jun 2023.
19. Pfizer Inc. Data from Pfizer's adult and pediatric clinical trial programs for 20-valent pneumococcal conjugate vaccine presented at IDWeek 2020 [media release]. 2020. https://www.pfizer.com/news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20 . Accessed 30 Jun 2023.
20. Pfizer Inc. U.S. FDA accepts Biologics License Application for Pfizer's respiratory syncytial virus maternal vaccine candidate for Priority Review [media release]. 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-biologics-license-application-pfizers . Accessed 30 Jun 2023.
21. Pfizer Inc. Form 10-K. Annual report pursuant to Section 13 or 15(d) of the Securites Exchange Act of 1934 for the fiscal year ended December 31, 2022. 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/78003/000007800323000024/pfe-20221231.htm#i8050b09ca8a0411dbcb0b6576ce1fc7a_46 . Accessed 30 Jun 2023.
22. Watson W. 20-valent pneumococcal conjugate vaccine (PCV20) phase 3 in pediatrics. In: ACIP February 22, 2023.
23. US FDA. Clinical review - PREVNAR 20. 2023. https://www.fda.gov/media/169126/download . Accessed 30 Jun 2023.
24. Senders S, Klein NP, Lamberth E, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J. 2021;40(10):944–51. [DOI: 10.1097/INF.0000000000003277]
25. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403–9. [DOI: 10.1056/NEJM200102083440602]
26. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187–95. [DOI: 10.1097/00006454-200003000-00003]
27. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–6. [DOI: 10.1097/00006454-200301000-00006]

MeSH Term

Chemicals